<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/Genscript-2025-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/Genscript-2025-430x241.jpg"/>
                                    
                                    <figcaption>Safety, durability and scalability are some of the main factors driving investment decisions in the cell and gene therapy space, say industry representatives. Image credit: Jam Bensilum / GlobalData.</figcaption>
                                </figure>
                            </div>
                                             
     
<figure class="wp-block-image size-large"></figure>



<p>As confidence grows for innovative in vivo strategies, some investors are saying they could be the future of the cell and gene therapy (CGT) sector.</p>



<p>In recent months, several high-profile deals have taken place within the in vivo chimeric antigen receptor (CAR)-T space. Last month, Bristol Myers Squibb acquired Orbital Therapeutics for $1.5bn, shortly after Gilead Sciences bought Interius BioTherapeutics for $350m in September. In July, AbbVie acquired Capstan Therapeutics and its in vivo CAR-T therapy for up to $2.1bn.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Gene Therapy For Gastrointestinal Tract Cancer... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>Immuno-oncology in Pharmaceuticals: CAR-T cell-based compositions </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>During a panel discussion on innovation and investment at the GenScript Biotech Global Forum London 2025 held on 20 November, Matthieu Coutet from Sofinnova Partners said pharma and investors are moving towards in vivo approaches in the CGT space. Coutet added that these days, pharma are showing very little interest in investing in autologous cell therapy companies.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Despite the enthusiasm, in vivo gene therapy is still in its infancy with limited data in humans, said Laura Stoppel, partner at RA Capital Management.</p>



<p>Stoppel said she is “cautiously optimistic” about allogeneic approaches in autoimmune disease, and hence RA Capital Management is investing in the space, but more data is still needed. </p>



<p>Speaking about autoimmune diseases she said: “I think that’s a place where allogeneic actually has the potential to match the efficacy of autologous cell therapy, especially if you don’t need long term persistence of these cells.”  </p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Safety also remains a hurdle in the CGT space, with systemic therapies prompting investor caution.</p>



<p>Nonetheless, experts said there is scope to expand beyond the traditional fields of oncology with CGTs. For example, ophthalmology was identified as a key area for drug development. Daniela Couto, general partner at BioGeneration Ventures, highlighted Complement Therapeutics’ investigation in dry age-related macular degeneration (AMD) and geographic atrophy (GA) as an example of an investable CGT biotech working in an area of unmet need in a “huge indication”.</p><div id="slot-two"></div>



<p>“If we could do a gene therapy, one and done, we would change the way we’re treating patients with geographic atrophy,” she said. Panellists also described favourability among investors and pharma for locally administered gene therapies.</p>



<p>Another factor that investors are considering is the availability of alternate treatment options. With the development of cost-effective T-cell engagers, Couto said it is difficult to justify investing in cell therapies. She added that investors are largely drawn towards in situ delivery modalities, due to cost and complexity of production.</p>



<p>In addition, Stoppel highlighted that a biotech’s preparedness and investment in manufacturing capabilities is a key aspect of consideration when investing. She also said there is a need for more innovation to optimise manufacturing processes.</p>



<p><em>Cell &amp; Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva</em>.</p>



<p><em>Editorial content is independently produced and follows the </em>highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
                 <p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
Nominate Now

             </div>

GILD

GENE

<p>Investors are increasingly focusing on novel technologies in the cell and gene therapy (CGT) sector, particularly in vivo CAR-T therapies. Recent high-profile acquisitions include Bristol Myers Squibb's purchase of Orbital Therapeutics for $1.5bn and Gilead Sciences' acquisition of Interius BioTherapeutics for $350m. Despite enthusiasm, in vivo gene therapy is still in its early stages with limited human data. Safety, scalability, and manufacturing capabilities are key investment considerations. Experts see potential in expanding CGTs beyond oncology, with ophthalmology highlighted as a promising area.</p>

Investors bet on newer technology and indications for CGTs